Boehringer Ingelheim GmbH (BING)’s Pradaxa blood thinner won the recommendation of the U.K.’s medical-cost regulator to prevent strokes in people with a type of irregular heartbeat. Any decision about whether to start treatment with Pradaxa, chemically known as dabigatran, should be made after an “informed discussion about the risks and benefits of dabigatran compared with warfarin,” a half-century-old generic blood thinner that requires monitoring, the National Institute for Health and Clinical Excellence said today in a statement announcing its final guidance on the drug.
